A new Live attenuated Classical Swine Fever Vaccine (IVRI-CSF-BS) gets released today. The technology has been developed by a team of ICAR -Indian Veterinary Research Institute (IVRI), Izatnagar scientists.
- A patent for the same has already been submitted for the new invention.
What is Classical Swine Fever (Hog cholera)?
- It is a viral disease related to pigs which are highly contagious and usually spreads by infectious meat or meat products consumption by Pigs or contact of healthy Pigs with infected pigs or their feces or body fluids, etc.
- It is not known to affect humans.
- It is different from Swine Flu, which affects humans too.
- It causes high mortality with an annual loss of approx. Rs.4.299 billion.
- It is a biological preparation that is meant to improve immunity to a particular disease.
- The basic principle of Vaccination reports on the property of Memory of the immune system.
Live attenuated vaccines
- Such vaccines contain a version of the living microbe that has been weakened to an extent that it can’t cause disease.
- Some of the examples are the MMR Vaccine, Rotavirus, etc.
Which vaccine was used before Live attenuated CSF?
- A laminated (Attenuated by Passage through rabbits) CSF vaccine (Weybridge strain, UK) has been used in India since 1964 for controlling the disease.
Issues with the Lapinized CSF vaccine
- Large numbers of rabbits are sacrificed for each batch as only 50 doses are produced from a single rabbit spleen (Primarily a Blood filter)
- In order to do away sacrificing rabbits and increase productivity, IVRI had earlier developed a cell culture CSF vaccine by adapting the laminated vaccine virus in cell culture.
Cell culture refers to the removal of cells from an animal or plant and their subsequent growth in a favorable artificial environment (Fluid Medium) or under controlled conditions.
One Health Approach calls for dealing with human and animal health together in interaction with the environment in an integrated manner
- It is deemed an urgent need for protecting global health and secure livelihoods.
Prospects of the new Vaccine
- The vaccine virus has a very high titer (Way of expressing concentration) and lakhs of doses can be produced very easily in cell culture.
- Due to the very high titer of the vaccine virus, this vaccine would be the most economical.
- CSF vaccine costing around less than Rs 2/- per dose as against Rs 15-25/- of laminated CSF vaccine and Rs.30/dose (approx) for an imported Korean vaccine being used in the country.
- Besides, the new vaccine gives immunity for two years as compared to 3 to 6 months of protection under the current regime of vaccines.
- The new vaccine will be part of the Government’s One Health Initiative and result in huge savings as it will nip the spread of the virus at the animal stage so that it does not pass on to the human population.
- Owing to a huge demand for Transfer of Technology of this vaccine, it has huge export potential, especially with Nepal.